Xconomy

SEPTEMBER 30, 2020

That research is starting to pay off as the companies now look ahead to pivotal studies testing that compound in several inherited forms of the disorder. The study was small and was not designed to show statistical significance. The study was small and was not designed to show statistical significance.

Statistics 111

Statistics Study Report Research 111

Xconomy

NOVEMBER 15, 2017

Acorda reported cases of arangulocytosis, dangerously low levels of infection-fighting white blood cells, and some of them have led to sepsis and death. Ardsley, NY-based Acorda (NASDAQ: ACOR ) said Wednesday morning that it has seen troubling safety problems in a Phase 3 trial of its experimental Parkinson’s disease drug tozadenant.

Study 55

Study Report Marketing San Diego 55

Startup Professionals Musings

APRIL 27, 2011

Blogging has come a long way in the past few years, from a social release for narcissists, to today’s required vehicle for promoting your consulting business and gaining valuable online exposure. If you can’t justify both a web site and a blog, skip the old-fashioned web site, and make your blog do double duty as described below.

Blogging 91

Blogging Search Engine Optimization Services Writing 91

Xconomy

MARCH 5, 2020

A 20-patient Phase 1 study of an RNA drug discovered by Ionis Pharmaceuticals that is being tested as a treatment for Huntington’s disease by Roche was suspended after two reports of infections related to a device used to take samples of cerebral spinal fluid during the trial.

Sample 120

Sample Study Report San Diego 120

Xconomy

JUNE 11, 2020

Less than a month after reporting preliminary early-stage data for its experimental vaccine for the novel coronavirus, Moderna has finalized the plan for a Phase 3 test. The study, set to begin next month, is targeting enrollment of about 30,000 volunteers, Moderna (NASDAQ: MRNA ) announced Thursday.

Study 101

Study Report San Diego Research 101

Xconomy

APRIL 22, 2020

Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the COVID-19 pandemic—this could be a pivotal year for the field, said Isabelle de Cremoux, CEO and managing partner of Seventure Partners.

Class 138

Class Study Research Report 138

Xconomy

JULY 6, 2016

The Obama administration’s push to sign up one million Americans for a long-term health study will start in New York, Pittsburgh, Chicago, and Tucson, AZ, top health officials said today. The VA is running its own long-term study with nearly half a million participants so far.).

Study 59

Study PMI San Diego Sample 59

Xconomy

FEBRUARY 10, 2020

Two experimental drugs from Eli Lilly and Roche have failed a clinical trial testing them as treatments for a form of Alzheimer’s disease caused by certain genetic mutations, the companies reported Monday. Lilly (NYSE: LLY ) and Roche reported that the groups treated with their respective drugs did.

Study 81

Study Report San Diego Company 81

Xconomy

JULY 21, 2020

That trend continued Monday when Acadia (NASDAQ: ACAD ) reported it would end its efforts to advance the drug as an adjunctive treatment for major depressive disorder (MDD) after preliminary data from a Phase 3 trial indicated it failed to meet the study’s main goal.

San Diego 67

San Diego Study Report Company 67

Startup Professionals Musings

APRIL 15, 2010

Blogging has come a long way in the past few years, from a social release for narcissists, to today’s required vehicle for promoting your business and gaining valuable online exposure, ultimately bringing in more customers. Here are some tips I’ve gleaned from experience: Make your blog your website. Anchor blog in your domain name.

Blogging 48

Blogging Search Engine Optimization Startup Writing 48

Xconomy

NOVEMBER 2, 2018

Studies of CRISPR-Cas9 to treat human disease are about to start, too. This week, we reported on a new study that raises exactly that question. The gene-editing technology CRISPR-Cas9 is opening up new research avenues all the time, such as giving drug developers a cheaper, faster way to knock out genes in tumor cells.

Study 74

Study Startup Research Report 74

Xconomy

DECEMBER 4, 2018

Take the results of a Phase 3 study just reported today at the American Society of Hematology’s (ASH) yearly meeting in San Diego. The treatment landscape for multiple myeloma, a deadly cancer of the bone marrow that affects about 30,000 Americans every year, has changed significantly over the past decade.

San Diego 83

San Diego Study Report Blogging 83

Xconomy

DECEMBER 11, 2019

But the company is pinning its hopes on another Phase 3 study that will report data early next year. Iterum (NASDAQ: ITRM ) reported preliminary Phase 3 data late Tuesday for its antibiotic, sulopenem, which is being tested as a treatment for complicated intra-abdominal infections.

Study 52

Study Report San Diego Company 52

Xconomy

MAY 22, 2020

No major safety problems were reported and there were some indications that the injections elicited antibodies. But Phase 1 clinical trials are small, and it’s unknown whether those early results can be replicated in larger studies. Furthermore, Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 80

Study Report San Diego Blogging 80

Xconomy

JANUARY 28, 2020

Acceleron (NASDAQ: XLRN ) late Monday reported positive preliminary data from mid-stage tests of sotatercept in pulmonary arterial hypertension. The Cambridge, MA-based company is now eyeing a Phase 3 study that could lead to FDA approval. The drug’s prospects have changed for the better. Some analysts say the compound has blockbuster.

Study 73

Study Report San Diego Company 73

Xconomy

SEPTEMBER 15, 2016

That’s according to a report being released today by Connect, the local nonprofit group focused on technology and entrepreneurship. The Connect Innovation Report found that 405 software, technology, and life sciences startups were created last year in San Diego County.

San Diego 40

San Diego Report High Tech Study 40

Xconomy

AUGUST 14, 2020

Four years after its microbiome therapy failed in a mid-stage study, the company reported early positive data from a pivotal test of its treatment for a type of gut infection. The road of drug development is rife with detours and disappointments but Seres Therapeutics showed this week that course corrections can work.

Study 63

Study Course Report Company 63

Xconomy

NOVEMBER 26, 2018

[ Note: Ben Fidler co-authored this report.] This weekend, San Diego will host the annual American Society of Hematology conference, the largest U.S. medical gathering to get the latest on blood diseases, and a venue for updates on some of the most cutting-edge biotechnologies that only a few years ago seemed like science fiction.

Guide 96

Guide San Diego Study Conference 96

Startup Professionals Musings

MARCH 19, 2022

It pays to invest more in building remote relationships with these site owners, or spending quality time with podcasters and popular blog influencers. In this context, you might also offer free seminars of the latest trends in tax accounting, or reports on best practices that you sanction and practice in a given discipline.

Services 121

Services Technical Review Social Media Case Study 121

Xconomy

FEBRUARY 22, 2019

Intercept (NASDAQ: ICPT ) reported interim data from a Phase 3 study showing its drug, obeticholic acid (OCA), reduced liver scarring in NASH patients. This week, one company, Intercept Pharmaceuticals, solidified its lead. But how much will being first to the finish line mean when all is said and done?

News 86

News Study Report San Diego 86

Xconomy

OCTOBER 23, 2018

[ Ben Fidler co-authored this report.] Breast Cancer Patients with two different types of breast cancer got promising news at ESMO from studies exploring relatively new methods of treatment. The European Society for Medical Oncology is wrapping up its annual conference today, replete with clinical data from cancer’s front lines.

Conference 93

Conference Class Study News 93

Xconomy

DECEMBER 18, 2018

Today we’re circling back with the rest of the list, which includes studies of drugs for nonalcoholic steatohepatitis, cystic fibrosis, spinal muscular atrophy and more. Editor’s note: Alex Lash, Corie Lok, and Frank Vinluan contributed to these reports. Read on for the details.

Study 83

Study Report San Diego Company 83

Xconomy

SEPTEMBER 9, 2019

On Monday, Acadia (NASDAQ: ACAD ) reported that its drug, pimavanserin, met the goal of delaying relapse of psychosis in dementia patients compared to a placebo.

San Diego 74

San Diego Study Report Company 74

Both Sides of the Table

FEBRUARY 20, 2012

Tracy studied SEOMoz and several other online sources of SEO tips. So Tracy began keeping a blog about … (what else?) She became an authority on the topic and her blog helped her to both elevate her status in her industry as well as to bring great link juice to her website and improve her SEO.

Startup 363

Startup Entrepreneur SEO Venture Capital 363

Xconomy

DECEMBER 6, 2017

With part two, we’re previewing studies for migraine, brain cancer, lymphoma, peanut allergy, schizophrenia, the rare Hunter syndrome, and the flu. [ Ben Fidler, Corie Lok, and Frank Vinluan contributed to this report.]

Study 63

Study Report San Diego Company 63

Xconomy

JUNE 23, 2016

San Diego’s cybersecurity workforce has grown by nearly 15 percent over the past two years, according to a study released today by the Cyber Center of Excellence, a nonprofit industry group created to boost cybersecurity jobs and technologies in the region. Combs worked previously at the EDC and helped prepare the 2014 report.

San Diego 69

San Diego Study Outsource Development Report 69

Xconomy

DECEMBER 17, 2018

In June, the company said 10 of 37 patients with localized prostate cancer in its Phase 2b study who received the treatment reported a clinically significant response. Sophiris (NASDAQ: SPHS ) already had encouraging mid-stage clinical trial data testing one dose of its drug, topsalysin, in prostate cancer patients.

Slides 72

Slides San Diego Study News 72

Xconomy

JANUARY 24, 2017

That’s according to British recruitment firm Liftstream and its new study of biotech companies that went public in the recent boom years. If power in the business world is centered in the boardroom, women in biotech have a long way to go to get their fair share—and the venture community deserves much of the blame.

Report 40

Report Class Study Venture Capital 40

Xconomy

DECEMBER 22, 2016

Part one of our preview is here , with looks at key studies in lung cancer, Alzheimer’s disease, asthma, and more. In part two, we examine studies in leukemia, migraine, multiple sclerosis, Parkinson’s disease, postpartum depression, amyloidosis, and Zika virus vaccine.

Study 40

Study Report San Diego Company 40

Xconomy

AUGUST 1, 2017

Ciara Kennedy, who succeeded Mike Grey as Amplyx CEO late last year, said in an interview with Xconomy that the company plans to report results of its Phase 1 study at IDWeek, the annual infectious diseases conference that is set for early October in San Diego.

San Diego 67

San Diego Study Conference Report 67

Xconomy

JUNE 2, 2018

At the American Society of Clinical Oncology meeting this morning, Loxo (NASDAQ: LOXO ) reports that in a Phase 1 study, 30 of 39 evaluable patients. Loxo could later this year become only the second company to have such a drug on the market. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.

Study 56

Study Report Marketing San Diego 56

Xconomy

APRIL 21, 2017

Our own reporting focused this week on the fallout from high drug prices, with a look at the frustration of families whose children have had trouble gaining access to the first drug ever approved for the rare spinal muscular atrophy. Earth Day’s—nationwide Marches for Science.

Study 49

Study News Pricing Google 49

Xconomy

NOVEMBER 7, 2016

Up until this point, studies of an experimental drug from Biogen and Ionis Pharmaceuticals had focused on patients with the most severe form of a rare, potentially deadly genetic disorder called spinal muscular atrophy. Biogen enrolled 126 patients in the study; 84 got nusinersen while 42 got a placebo.

Help 97

Help Study Research Statistics 97

Both Sides of the Table

OCTOBER 10, 2011

Each with its own head, its own financial reporting and its own content strategy, pricing strategy and marketing strategy. Netflix announced the changes to its company via a blog post. A blog post! You don’t handle major announcements via a blog post and no touch points. Not a freakin’ blog post.

Netflix 287

Netflix Customer Custom Pricing 287

Xconomy

JUNE 27, 2016

Regulus reported that a second serious case of jaundice, or a yellowing of the skin and eyes, in a Phase 1 study of RG-101. Regulus said the hold won’t impact timelines for its three ongoing studies of RG-101, because it has already treated the patients in those trials—two Phase 2 studies and a single Phase 1 study.

Study 52

Study News Report Conference 52

Xconomy

DECEMBER 21, 2016

[Editor’s note: Alex Lash and Frank Vinluan contributed to this report.] After years of research, frustration, hype, and millions (sometimes hundreds of millions) of dollars invested, a drug program boils down to the clinical data—usually from big, late-stage studies—that can sometimes make or break a company.

Study 40

Study Report Research Invest 40

Xconomy

JANUARY 11, 2017

While we’re looking at venture deal numbers from the past year , let’s consider the education technology industry, which isn’t broken out by sector in the general reports I’ve seen. A recent study by EdSurge , an edtech information firm, shows venture funding for U.S. The EdSurge report.

Funding 40

Funding Education Venture Capital Study 40